Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 4,002 |
|
|||||
| News | - | ||||||
| Day High | 9.1425 | Low High |
|||||
| Day Low | 8.615 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Oncternal Therapeutics Inc | ONCT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.26 | 2.99% | 8.95 | 16:30:41 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.80 | 8.615 | 9.1425 | 8.95 | 8.69 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 105 | 4,002 | $ 8.89 | $ 35,588 | - | 5.5656 - 13.14 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 95 | $ 8.71 | USD |
Oncternal Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 26.49M | 2.96M | - | 785k | -39.48M | -13.34 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Oncternal Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ONCT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.52 | 9.48 | 8.52 | 8.88 | 9,380 | 0.43 | 5.05% |
| 1 Month | 7.85 | 9.852 | 7.81 | 8.74 | 7,597 | 1.10 | 14.01% |
| 3 Months | 6.81 | 10.613 | 6.6901 | 9.11 | 10,060 | 2.14 | 31.42% |
| 6 Months | 5.76 | 13.14 | 5.5656 | 8.37 | 140,050 | 3.19 | 55.38% |
| 1 Year | 6.70 | 13.14 | 5.5656 | 7.46 | 190,122 | 2.25 | 33.58% |
| 3 Years | 128.00 | 137.798 | 5.22 | 48.26 | 476,769 | -119.05 | -93.01% |
| 5 Years | 137.40 | 211.20 | 5.22 | 75.80 | 665,246 | -128.45 | -93.49% |
Oncternal Therapeutics Description
| Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. |
